Developed in collaboration with REPROCELL, CELLvo™ Atrial Cardiomyocyte delivers non-genetically modified human heart cells that are chamber specific and derived from iPS (stem) cells SAN ANTONIO, June 13, 2023 /PRNewswire/ — StemBioSys, Inc. (StemBioSys) announced today the launch of CELLvo™ Atrial Cardiomyocyte, a “chamber specific” human induced pluripotent stem cell derived cardiomyocyte (hiPSC-CM) designed to […]